Laura Kunze
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Kunze has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Pollreisz
Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
2 shared publications - Bianca S. Gerendas
Medical University of Vienna
1 shared publication - Elisabeth Brunner
Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Wien, Austria
1 shared publication - Heiko Stino
Department of Ophthalmology, Medical University of Vienna, 1090 Vienna, Austria
1 shared publication - Irene Steiner
Institute of Medical Statistics, Center for Medical Data Science, Medical University of Vienna, 1090 Vienna, Austria
1 shared publication - Katharina Kriechbaum
Department of Ophthalmology, Medical University of Vienna, 1090 Vienna, Austria
1 shared publication
Latest Publications
- Open Access
- 13 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3747
First-Line Faricimab in Diabetic Macular Edema: Insights from a Real-World Treatment-Naïve Population in Austria
Background: Diabetic macular edema (DME) is a leading cause of vision loss. Although real-world data on faricimab, a bispecific antibody targeting vascular endothelial growth factor-A and Angiopoietin-2, are expanding, its long-term durability in routine clinical practice has not yet been fully established. We evaluated effectiveness, anatomic response and treatment durability of first-line faricimab in treatment-naïve DME. Methods: We conducted a single-center, retrospective cohort study of treatment-naïve DME eyes initiated on intravitreal faricimab (August 2023–October 2024) in a real-world setting. After a loading phase, eyes were managed with a treat-and-extend or pro re nata regimen. The primary endpoint was retreatment interval at 48 weeks. Secondary endpoints were retreatment interval at weeks 12, 24 and 36; change in visual acuity (VA); central subfield thickness (CST); and optical coherence tomography (OCT) fluid. Results: Fifty-two eyes from 40 consecutive patients were included (baseline VA 65.96 ± 13.55 letters; CST 426.56 ± 106.72 µm). Mean injections were 4.02 ± 1.11 between months 1–6 and 1.90 ± 0.98 between months 7–12. VA improved by +8.46, +7.57, +7.65 and +7.72 letters at 12, 24, 36, and 48 weeks (all p < 0.0001), respectively. Relative CST decreased by −28.05%, −27.01%, −29.46% and −25.22% at the same time points (all p < 0.0001). At week 48, 15.4% of eyes were on a treatment interval of less than 12 weeks, 23.1% were between 12 and 16 weeks, and 46.1% were on 16 or more weeks; 15.4% were managed PRN. Conclusions: First-line faricimab in treatment-naïve DME in a real-world setting yielded clinically meaningful and durable extensions in treatment intervals, alongside sustained functional and anatomical improvements.
- 13 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (10) , 3747
Open AccessFirst-Line Faricimab in Diabetic Macular Edema: Insights from a Real-World Treatment-Naïve Population in Austria
Background: Diabetic macular edema (DME) is a leading cause of vision loss. Although real-world data on faricimab, a bispecific antibody targeting vascular endothelial growth factor-A and Angiopoietin-2, are expanding, its long-term durability in routine clinical practice has not yet been fully established. We evaluated effectiveness, anatomic response and treatment durability of first-line faricimab in treatment-naïve DME. Methods: We conducted a single-center, retrospective cohort study of treatment-naïve DME eyes initiated on intravitreal faricimab (August 2023–October 2024) in a real-world setting. After a loading phase, eyes were managed with a treat-and-extend or pro re nata regimen. The primary endpoint was retreatment interval at 48 weeks. Secondary endpoints were retreatment interval at weeks 12, 24 and 36; change in visual acuity (VA); central subfield thickness (CST); and optical coherence tomography (OCT) fluid. Results: Fifty-two eyes from 40 consecutive patients were included (baseline VA 65.96 ± 13.55 letters; CST 426.56 ± 106.72 µm). Mean injections were 4.02 ± 1.11 between months 1–6 and 1.90 ± 0.98 between months 7–12. VA improved by +8.46, +7.57, +7.65 and +7.72 letters at 12, 24, 36, and 48 weeks (all p < 0.0001), respectively. Relative CST decreased by −28.05%, −27.01%, −29.46% and −25.22% at the same time points (all p < 0.0001). At week 48, 15.4% of eyes were on a treatment interval of less than 12 weeks, 23.1% were between 12 and 16 weeks, and 46.1% were on 16 or more weeks; 15.4% were managed PRN. Conclusions: First-line faricimab in treatment-naïve DME in a real-world setting yielded clinically meaningful and durable extensions in treatment intervals, alongside sustained functional and anatomical improvements.
- Open Access
- 10 February 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (4) , 429
Image Quality in Adaptive Optics Optical Coherence Tomography of Diabetic Patients
Background/Objectives: An assessment of the retinal image quality in adaptive optics optical coherence tomography (AO-OCT) is challenging. Many factors influence AO-OCT imaging performance, leading to greatly varying imaging results, even in the same subject. The aim of this study is to introduce quantitative means for an assessment of AO-OCT image quality and to compare these with parameters retrieved from the pyramid wavefront sensor of the system. Methods: We used a spectral domain AO-OCT instrument to repetitively image six patients suffering from diabetic retinopathy over a time span of one year. The data evaluation consists of two volume acquisitions with a focus on the photoreceptor layer, each at five different retinal locations per visit; 7–8 visits per patient are included in this data analysis, resulting in a total of ~420 volumes. Results: A large variability in AO-OCT image quality is observed between subjects and between visits of the same subject. On average, the image quality does not depend on the measurement location. The data show a moderate correlation between the axial position of the volume recording and image quality. The correlation between pupil size and AO-OCT image quality is not linear. A weak correlation is found between the signal-to-noise ratio of the wavefront sensor image and the image quality. Conclusions: The introduced AO-OCT image quality metric gives useful insights into the performance of such a system. A longitudinal assessment of this metric, together with wavefront sensor data, is essential to identify factors influencing image quality and, in the next step, to optimize the performance of AO-OCT systems.
- 10 February 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (4) , 429
Open AccessImage Quality in Adaptive Optics Optical Coherence Tomography of Diabetic Patients
Background/Objectives: An assessment of the retinal image quality in adaptive optics optical coherence tomography (AO-OCT) is challenging. Many factors influence AO-OCT imaging performance, leading to greatly varying imaging results, even in the same subject. The aim of this study is to introduce quantitative means for an assessment of AO-OCT image quality and to compare these with parameters retrieved from the pyramid wavefront sensor of the system. Methods: We used a spectral domain AO-OCT instrument to repetitively image six patients suffering from diabetic retinopathy over a time span of one year. The data evaluation consists of two volume acquisitions with a focus on the photoreceptor layer, each at five different retinal locations per visit; 7–8 visits per patient are included in this data analysis, resulting in a total of ~420 volumes. Results: A large variability in AO-OCT image quality is observed between subjects and between visits of the same subject. On average, the image quality does not depend on the measurement location. The data show a moderate correlation between the axial position of the volume recording and image quality. The correlation between pupil size and AO-OCT image quality is not linear. A weak correlation is found between the signal-to-noise ratio of the wavefront sensor image and the image quality. Conclusions: The introduced AO-OCT image quality metric gives useful insights into the performance of such a system. A longitudinal assessment of this metric, together with wavefront sensor data, is essential to identify factors influencing image quality and, in the next step, to optimize the performance of AO-OCT systems.